APONTIS PHARMA AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.28 EUR | -0.48% |
|
+2.73% | +74.32% |
| Apr. 05 | Apontis Bags Distribution Deal with Novartis Unit for Two Asthma Medications | MT |
| Mar. 28 | Apontis Pharma AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2024 * | 51.07M 54.6M | Sales 2025 * | 58.83M 62.91M | Capitalization | 68.97M 73.75M |
|---|---|---|---|---|---|
| Net income 2024 * | 1M 1.07M | Net income 2025 * | 3M 3.21M | EV / Sales 2024 * | 1.13 x |
| Net cash position 2024 * | 11.27M 12.05M | Net cash position 2025 * | 12M 12.83M | EV / Sales 2025 * | 0.97 x |
| P/E ratio 2024 * |
69
x | P/E ratio 2025 * |
19.1
x | Employees | 177 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98% |
More Fundamentals
* Assessed data
More news
Latest transcript on Apontis Pharma AG
More press releases
More news
| 1 day | -0.48% | ||
| 1 week | +2.73% | ||
| Current month | +30.19% | ||
| 1 month | +33.55% | ||
| 3 months | +88.18% | ||
| 6 months | +142.82% | ||
| Current year | +74.32% |
1 week
7.88
8.50
1 month
6.468.88
Current year
4.128.88
1 year
3.0311.85
3 years
3.0327.80
5 years
3.0327.80
10 years
3.0327.80
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | - | |
| Director of Finance/CFO | - | 21-12-31 | |
Olaf Randerath
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Edin Hadzic
BRD | Director/Board Member | 53 | 20-12-31 |
Olaf Elbracht
BRD | Director/Board Member | 59 | 20-12-31 |
| Chairman | 51 | 20-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 8.28 | -0.48% | 3,932 |
| 24-04-25 | 8.32 | +2.21% | 5,325 |
| 24-04-24 | 8.14 | +0.99% | 3,304 |
| 24-04-23 | 8.06 | -0.25% | 1,145 |
| 24-04-22 | 8.08 | +0.25% | 746 |
Delayed Quote Xetra, April 26, 2024 at 11:36 am EDT
More quotes
Apontis Pharma AG is a Germany-based manufacturer of pharmaceutical preparation. The company focuses on the commercialization of pharmaceutical products to General Practitioners and engages in the marketing and sale of medical drugs for indication fields of internal medicine in Germany.
Sector
Pharmaceuticals
Calendar
2024-05-07
- Q1 2024 Earnings Call
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
8.28
EUR
Average target price
17.5
EUR
Spread / Average Target
+111.35%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +74.32% | 73.63M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- APPH Stock
